Biopharma IPOs: Timing, capital and staying flexible

FierceBiotechWhy Execution Excellence Now Defines Biopharma Winners

FierceBiotechHow integrated strategy is reshaping biopharma growth

FierceBiotechBiotech value creation at an inflection point

FierceBiotechGSK pledges £44.5M in near-term for UK biotech to explore cause of liver fibrosis regression

PharmaVoice3 potential takeover targets in obesity

FierceBiotechHow Unlearn is building a scientific intelligence layer for clinical development

FierceBiotechHow AI is reshaping biopharma decision-making

FierceBiotechBiopharma IPOs: Timing, capital and staying flexible

Roche MediaRoche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics - Pharmaceutical Technology

Endpoints NewsIncyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront deal

Endpoints NewsTakeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appeal

Endpoints NewsNurix to work with Roche on BTK degrader in deal worth up to $2.3B